Escugen and Sovran expand collaboration to co-develop pan-tumour bispecific ADC
Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.
The programme will combine MICA/B targeting with a second tumour-associated target using an AND-gated design intended to improve tumour selectivity across multiple cancer types.
The agreement advances the companies' relationship from research collaboration into joint development of a potentially first-in-class ADC programme, with financial terms undisclosed.
Field | Content |
Alert Type | Deal |
Companies | Escugen Biotechnology; Sovran Biosciences |
Deal Type | Co-development agreement |
Asset or Company | Pan-tumour bispecific antibody-drug conjugate programme |
Therapy Area(s) | Oncology; solid tumours |
Technology or Modality | Bispecific antibody-drug conjugate; AND-gated targeting |
Targets | MICA/B plus a second tumour-associated target |
Deal Value | Financial terms were not disclosed |
Geography | Global |
What Happened | Escugen and Sovran expanded their existing collaboration into a co-development agreement for a bispecific ADC intended to target multiple tumour types. |
Why It Matters | The programme uses dual-target recognition designed to increase tumour selectivity, potentially improving therapeutic index compared with conventional single-target ADCs. |
Supporting Context | The AND-gated strategy requires recognition of MICA/B and a second tumour-associated target to enhance preferential activity against cancer cells. |
Strategic Rationale | Escugen and Sovran are combining complementary antibody-engineering and oncology-development capabilities to advance a differentiated ADC platform. |
Potential Impact | If successful, the approach could support development of a broadly applicable ADC with improved specificity across multiple solid tumours. |
Key Takeaway | Escugen and Sovran have moved into joint development of a pan-tumour bispecific ADC based on dual-target recognition. |
What to Watch | Selection of the second tumour target, candidate nomination and progression into preclinical and clinical development. |
Primary Source | Escugen Biotechnology / Sovran Biosciences |
Relevant Date | 16 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments